Search Results

You are looking at 21 - 30 of 34 items for :

  • "hormone replacement therapy" x
Clear All
Full access

Kostandinos Sideras and Charles L. Loprinzi

recurrence after hormone replacement therapy in breast cancer survivors . J Natl Cancer Inst 2008 ; 100 : 475 – 482 . 19. von S choultz E Rutqvist LE . Menopausal hormone therapy after breast cancer: the Stockholm randomized trial . J Natl

Full access

Therese B. Bevers, John H. Ward, Banu K. Arun, Graham A. Colditz, Kenneth H. Cowan, Mary B. Daly, Judy E. Garber, Mary L. Gemignani, William J. Gradishar, Judith A. Jordan, Larissa A. Korde, Nicole Kounalakis, Helen Krontiras, Shicha Kumar, Allison Kurian, Christine Laronga, Rachel M. Layman, Loretta S. Loftus, Martin C. Mahoney, Sofia D. Merajver, Ingrid M. Meszoely, Joanne Mortimer, Lisa Newman, Elizabeth Pritchard, Sandhya Pruthi, Victoria Seewaldt, Michelle C. Specht, Kala Visvanathan, Anne Wallace, Mary Ann Bergman and Rashmi Kumar

-ranging trial of tamoxifen at low doses in hormone replacement therapy users . J Clin Oncol 2007 ; 25 : 4201 – 4209 . 144. Sideras K Ingle JN Ames MM . Coprescription of tamoxifen and medications that inhibit CYP2D6 . J Clin Oncol 2010 ; 28

Full access

Jill R. Tichy, Elgene Lim and Carey K. Anders

cancer incidence, partly because of a lower use of hormone replacement therapy. 6 In contrast, breast cancer incidence in women younger than 45 years remains stable. 7 In the United States, approximately 200,000 breast cancer cases are reported per year

Full access

Douglas E. Wood, George A. Eapen, David S. Ettinger, Lifang Hou, David Jackman, Ella Kazerooni, Donald Klippenstein, Rudy P. Lackner, Lorriana Leard, Ann N. C. Leung, Pierre P. Massion, Bryan F. Meyers, Reginald F. Munden, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Michael Unger and Stephen C. Yang

are at a higher risk of developing lung cancer than those without fibrosis. 59 Hormone Replacement Therapy Whether hormone replacement therapy (HRT) use affects the risk of lung cancer in women is currently unclear. More than 20 studies have

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Tanya Siddiqi, Judy L. Smith, Gary C. Yee, Anaadriana Zakarija, Nicole McMillian and Maoko Naganuma

-positive cancers. 47 - 51 The use of hormonal compounds such as hormone replacement therapy 52 , 53 or oral contraceptive agents 54 - 57 has also been associated with increased risk of developing VTE. Recent case-control studies and meta-analyses suggested that

Full access

Crystal S. Denlinger, Tara Sanft, K. Scott Baker, Shrujal Baxi, Gregory Broderick, Wendy Demark-Wahnefried, Debra L. Friedman, Mindy Goldman, Melissa Hudson, Nazanin Khakpour, Allison King, Divya Koura, Elizabeth Kvale, Robin M. Lally, Terry S. Langbaum, Michelle Melisko, Jose G. Montoya, Kathi Mooney, Javid J. Moslehi, Tracey O'Connor, Linda Overholser, Electra D. Paskett, Jeffrey Peppercorn, M. Alma Rodriguez, Kathryn J. Ruddy, Paula Silverman, Sophia Smith, Karen L. Syrjala, Amye Tevaarwerk, Susan G. Urba, Mark T. Wakabayashi, Phyllis Zee, Deborah A. Freedman-Cass and Nicole R. McMillian

. Holmberg L Iversen OE Rudenstam CM . Increased risk of recurrence after hormone replacement therapy in breast cancer survivors . J Natl Cancer Inst 2008 ; 100 : 475 – 482 . 114. Fahlen M Fornander T Johansson H . Hormone replacement therapy

Full access

Michael B. Streiff, Paula L. Bockenstedt, Spero R. Cataland, Carolyn Chesney, Charles Eby, John Fanikos, Patrick F. Fogarty, Shuwei Gao, Julio Garcia-Aguilar, Samuel Z. Goldhaber, Hani Hassoun, Paul Hendrie, Bjorn Holmstrom, Kimberly A. Jones, Nicole Kuderer, Jason T. Lee, Michael M. Millenson, Anne T. Neff, Thomas L. Ortel, Judy L. Smith, Gary C. Yee and Anaadriana Zakarija

certain estrogen receptor-positive cancers. 46 - 50 Use of estrogenic compounds, such as hormone replacement therapy 51 , 52 or oral contraceptive agents, 53 , 54 has also been associated with increased risk of developing VTE. Diethylstilbestrol

Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent and Jeffrey D. Wayne

manageable with thyroid hormone replacement therapy. Both of these adverse events have also been associated with the long-term use of sunitinib on intermittent dosing. The results of this study suggest that continuous daily dosing appears to be an effective

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

, increasing patient age, family history of breast cancer at a young age, early menarche, late menopause, older age at first live childbirth, prolonged hormone replacement therapy, previous exposure to therapeutic chest wall irradiation, benign proliferative

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead and Rashmi Kumar

cancer at a young age, early menarche, late menopause, nulliparity, older age at first live child-birth, prolonged combined hormone replacement therapy, previous exposure to therapeutic chest wall irradiation, benign proliferative breast disease